Caspofungin (CAS) is used to prevent and treat invasive fungal infections patients older than 3 months. However, the optimal dosing strategy of CAS is lacking in adolescents from 12 to 17 years old, especially those undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), who are vulnertable to fungal infections. The study aimed to establish a population pharmacokinetic (PPK) model and assess the dosing schemes of CAS in adolescents with allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study Type
OBSERVATIONAL
Enrollment
30
No specific interventions were administrated. Participants receive interventions as part of routine medical care, where CAS was infused intravenously over 60 min at a loading dose of 70 mg/m2 on day 1, followed by a maintenance dose of 50 mg/m2 (maximum: 70 mg daily).
Wuhan Children's Hospital
Wuhan, China
The PTAs of AUC24/MIC90 for C. albicans , C. glabrata , and C. parapsilosis
The probability of target attainment (PTA) of the ratio of AUC24 (area under the concentration-time curve from 0 to 24 hours) and MIC90 (the lowest concentration of caspofungin at which 90% of the isolates were inhibited) (AUC24/MIC90) for C. albicans (0.06 mg/L), C. glabrata (450 mg/L), and C. parapsilosis (1185 mg/L) .
Time frame: 1 day
The PTAs of AUC24/MIC for various species of Candida spp isolates
The probability of target attainment (PTA) of the ratio of AUC24 (area under the concentration-time curve from 0 to 24 hours) and MIC (minimal inhibitory concentration) (AUC24/MIC) for various species of Candida spp isolates with a MIC range of 0.03 to 1.0 mg/L
Time frame: 1 day
The PTAs of trough concentration
PTA of patients with CAS trough concentration ≥ 1 μg/mL
Time frame: the trough concentration (24 hours after administration) at the steady state
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.